Andrew Tsai
Stock Analyst at Jefferies
(3.79)
# 757
Out of 5,241 analysts
31
Total ratings
59.26%
Success rate
8.46%
Average return
Main Sectors:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AXSM Axsome Therapeutics | Maintains: Buy | $245 → $275 | $227.72 | +20.76% | 3 | May 4, 2026 | |
| CMPS COMPASS Pathways | Initiates: Buy | $18 | $10.37 | +73.58% | 1 | May 4, 2026 | |
| DRUG Bright Minds Biosciences | Initiates: Buy | $145 | $77.47 | +87.17% | 1 | Apr 13, 2026 | |
| DFTX Definium Therapeutics | Initiates: Buy | $30 | $20.99 | +42.93% | 1 | Jan 30, 2026 | |
| VTGN Vistagen Therapeutics | Downgrades: Hold | $15 → $0.9 | $0.62 | +44.02% | 3 | Dec 17, 2025 | |
| MRNA Moderna | Initiates: Hold | $30 | $49.04 | -38.83% | 1 | Dec 12, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $300 → $450 | $342.58 | +31.36% | 2 | Dec 9, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Buy | $32 | $28.73 | +11.38% | 1 | Nov 21, 2025 | |
| ANRO Alto Neuroscience | Maintains: Buy | $15 → $25 | $22.98 | +8.79% | 2 | Nov 12, 2025 | |
| BIIB Biogen | Initiates: Buy | $190 | $192.95 | -1.53% | 1 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $17.55 | +99.43% | 3 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $30.08 | -0.27% | 1 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $66.13 | +5.85% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $29 → $2.5 | $3.25 | -23.08% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $27 | $18.17 | +48.60% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $3.5 → $13 | $6.90 | +88.41% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $37.07 | -5.58% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $3 | $2.23 | +34.53% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $4.02 | +572.48% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $54.39 | -57.71% | 1 | Jun 1, 2020 |
Axsome Therapeutics
May 4, 2026
Maintains: Buy
Price Target: $245 → $275
Current: $227.72
Upside: +20.76%
COMPASS Pathways
May 4, 2026
Initiates: Buy
Price Target: $18
Current: $10.37
Upside: +73.58%
Bright Minds Biosciences
Apr 13, 2026
Initiates: Buy
Price Target: $145
Current: $77.47
Upside: +87.17%
Definium Therapeutics
Jan 30, 2026
Initiates: Buy
Price Target: $30
Current: $20.99
Upside: +42.93%
Vistagen Therapeutics
Dec 17, 2025
Downgrades: Hold
Price Target: $15 → $0.9
Current: $0.62
Upside: +44.02%
Moderna
Dec 12, 2025
Initiates: Hold
Price Target: $30
Current: $49.04
Upside: -38.83%
Praxis Precision Medicines
Dec 9, 2025
Maintains: Buy
Price Target: $300 → $450
Current: $342.58
Upside: +31.36%
MapLight Therapeutics
Nov 21, 2025
Initiates: Buy
Price Target: $32
Current: $28.73
Upside: +11.38%
Alto Neuroscience
Nov 12, 2025
Maintains: Buy
Price Target: $15 → $25
Current: $22.98
Upside: +8.79%
Biogen
Sep 25, 2025
Initiates: Buy
Price Target: $190
Current: $192.95
Upside: -1.53%
Jul 24, 2025
Maintains: Buy
Price Target: $40 → $35
Current: $17.55
Upside: +99.43%
Jul 18, 2025
Initiates: Buy
Price Target: $30
Current: $30.08
Upside: -0.27%
Jul 14, 2025
Initiates: Buy
Price Target: $70
Current: $66.13
Upside: +5.85%
May 28, 2025
Downgrades: Hold
Price Target: $29 → $2.5
Current: $3.25
Upside: -23.08%
Mar 19, 2025
Maintains: Overweight
Price Target: $19 → $27
Current: $18.17
Upside: +48.60%
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $6.90
Upside: +88.41%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $37.07
Upside: -5.58%
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $2.23
Upside: +34.53%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $4.02
Upside: +572.48%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $54.39
Upside: -57.71%